Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novavax, Inc. stock logo
NVAX
Novavax
$10.34
+0.2%		$8.57
$6.20
▼
$11.97
$1.70B2.455.17 million shs6.21 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novavax, Inc. stock logo
NVAX
Novavax
+1.98%+12.05%+39.27%+1.28%+36.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novavax, Inc. stock logo
NVAX
Novavax
$10.34
+0.2%		$8.57
$6.20
▼
$11.97
$1.70B2.455.17 million shs6.21 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novavax, Inc. stock logo
NVAX
Novavax
+1.98%+12.05%+39.27%+1.28%+36.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$14.0035.40% Upside

Current Analyst Ratings Breakdown

Latest NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/4/2026
Novavax, Inc. stock logo
NVAX
Novavax
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/11/2026
Novavax, Inc. stock logo
NVAX
Novavax
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$19.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.52$3.52 per share2.94($1.16) per share-8.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)

Latest NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30

Institutional Ownership

CompanyInstitutional Ownership
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.95 million162.31 millionOptionable

Recent News About These Companies

Novavax to Participate in September Investor Conferences
September 2 at 7:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-participate-september-investor-conferences-210000338.html
Novavax to Participate in September Investor Conferences
September 2 at 5:00 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/novavax-to-participate-in-september-investor-conferences-302867780.html
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor
September 2 at 9:30 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61573251/novavax-stock-rises-despite-no-confirmed-news-behind-the-matrix-m-rumor
What's going on with Novavax stock?
September 1 at 6:10 PM  |  msn.comhttps://www.msn.com/en-us/news/other/what-s-going-on-with-novavax-stock/ar-AA2bmfh9
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
September 1 at 1:31 PM  |  247wallst.comhttps://247wallst.com/investing/2026/09/01/novavax-jumps-6-on-matrix-m-oncology-speculation-is-the-royalty-model-the-real-story/
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
September 1 at 1:12 PM  |  247wallst.comhttps://247wallst.com/investing/2026/09/01/novavax-jumps-6-on-matrix-m-oncology-speculation-is-the-royalty-model-the-real-story/?utm_source=snapi
What's Going On With Novavax Stock?
September 1 at 1:11 PM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61555730/whats-going-on-with-novavax-stock-2
Novavax (NASDAQ:NVAX) Shares Up 5.3% - Here's What Happened
August 31 at 12:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-novavax-nasdaq-nvax-shares-up-53-heres-what-happened-2026-08-31/
Novavax Stock Climbs Monday: What's Going On?
August 31 at 12:00 PM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/08/61526631/novavax-stock-climbs-monday-whats-going-on
Research Analysts Set Expectations for Novavax Q3 Earnings
August 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30991307
How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative
August 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/expanded-nuvaxovid-royalties-partner-led-190520474.html
Has Novavax (NVAX) Fallen Far Enough To Look Cheap?
August 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-nvax-fallen-far-enough-130622971.html
Novavax (NVDA) Following Updated Nuvaxovid Approval Faces A Wide Fair Value Debate
August 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-nvda-following-updated-nuvaxovid-170451700.html
Novavax's Nuvaxovid Approved in US, EU, Japan for 2026-2027 Season
August 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-apos-nuvaxovid-approved-us-130419318.html
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
August 28, 2026  |  stocktwits.comS
Novavax's XFG-Adapted Nuvaxovid Approved In U.S., EU, Japan For 2026-2027 Season
August 28, 2026  |  rttnews.comhttps://www.rttnews.com/3686496/novavax-s-xfg-adapted-nuvaxovid-approved-in-u-s-eu-japan-for-2026-2027-season.aspx
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
August 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavaxs-partnership-strategy-continues-deliver-123000950.html
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
August 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/novavaxs-partnership-strategy-continues-to-deliver-with-xfg-adapted-nuvaxovid-approvals-in-the-us-eu-and-japan-for-2026-2027-vaccination-season-302862775.html
Zacks Research Has Negative Outlook for Novavax Q3 Earnings
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-has-negative-outlook-for-novavax-q3-earnings-2026-08-28/
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
August 27, 2026  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/08/61484141/quick-spark-fda-approves-updated-covid-vaccines-from-moderna-pfizer-novavax
US FDA approves updated COVID vaccines for 2026-27 season
August 27, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-updated-covid-vaccines-2026-27-season-2026-08-27/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Novavax stock logo

Novavax NASDAQ:NVAX

$10.34 +0.02 (+0.19%)
As of 04:00 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas